

**Pharmacokinetics of ANTINEOPLASTON A10 AND AS2-1  
in Patients**

**with Neoplastic disease**

**Robert J. Waldbillig, Ph.D.**

**Vice President of Research**

**Burzynski Research Institute**

**January 15, 1998**

**Translated into ug/mL from page 22 of 1998 FDA report on ANP**

Plasma Antineoplaston Levels in Patients During Treatment

Name of Antineoplaston Ingredient	Plasma Levels ( $\mu\text{g/mL}$ )		Ratio
	Mayo Clinic (MC)	Burzynski Clinic (BC)	BC/MC
PG	302	11088	36 x higher
IsoPG	14 to 35	2376	67-169 x higher
PN	177	476	2.7 x higher